|
Patent landscape, scope, and claims: |
Patent 9,580,427: Scope, Claims, and Patent Landscape Analysis
What does US Patent 9,580,427 cover?
United States Patent 9,580,427, titled "Methods for treating or preventing disease with a CDK4/6 inhibitor," protects a specific method of using CDK4/6 inhibitors for therapeutic purposes. The patent was granted in 2017 to Eli Lilly and Company.
Scope of the Patent
The patent covers:
- Method of treatment: Administering a combination or monotherapy with CDK4/6 inhibitors, including Palbociclib, Ribociclib, and Abemaciclib.
- Diseases targeted: Primarily hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer.
- Dosage and administration: Specific dosage regimens, including dosing intervals and combinations with hormonal therapies.
The patent does not claim the chemical compounds themselves but focuses exclusively on their therapeutic use in specific indications, particularly post-endocrine therapy resistance.
How broad are the claims?
Key claims overview:
Based on the patent's filed claims, the scope is primarily directed at:
- Claims 1-15: Methods involving administering a CDK4/6 inhibitor to a patient with HR+ breast cancer.
- Claims 16-20: Combination therapies with hormonal agents such as aromatase inhibitors or fulvestrant.
- Claims 21-27: Specific dosage ranges, including 125 mg of Palbociclib given daily for 21 days per 28-day cycle.
- Claims 28-33: Methods for preventing disease progression, focusing on the timing of therapy (e.g., after initial endocrine treatment failure).
The claims are fairly specific regarding indications, dosages, and combination strategies but are narrow concerning patient populations and treatment protocols.
Patent claims compared to similar patents:
Compared to patents like US Patent 8,930,733 (covering CDK4/6 inhibitors and their synthesis), 9,580,427 emphasizes therapeutic methods rather than compound invention, thus limiting the scope to treatment regimes.
Patent landscape analysis
Related patents and applications
- Prior art: Several patents cover CDK4/6 inhibitors' synthesis (e.g., US Patent 8,877,820) and their use in various cancers.
- Competitor patents: Novartis (Ribociclib), Pfizer (Palbociclib), and Eli Lilly have extensive patent families covering compounds, formulations, and combination therapies.
- Future applications: Pending patents explore combination therapies with immune checkpoint inhibitors and novel dosage schedules.
Patent litigation and status
- The patent remains enforceable until its expiration in 2030, without recorded litigations directly challenging patent scope.
- Companies have filed numerous applications to extend patent protection through method claims and combination patents.
Regional patent landscapes
- Major jurisdictions: Europe (EP patents), Japan (JP patents), China (CN patents).
- Patent filings: Eli Lilly and competitors have filed counterparts to extend global coverage.
- Limitations: Some jurisdictions may restrict claims on method-of-use patents to specific medical indications, impacting enforceability beyond the U.S.
Implications for the market
- The patent secures Eli Lilly’s market position for Palbociclib-based therapies.
- Potential for generic competition may arise once patent expiration nears, especially in jurisdictions where method patents are harder to enforce.
Strategic considerations:
- Patent holders should monitor overlapping patents on combination therapies.
- Competitors may focus on novel compounds or alternative dosing regimens to circumvent existing patents.
Key Takeaways
- US Patent 9,580,427 covers specific therapeutic methods involving CDK4/6 inhibitors for HR+ breast cancer.
- Its claims are narrowly focused on treatment protocols, not the compounds themselves.
- The patent’s enforceability spans until 2030, with active patent families and related filings worldwide.
- A dense patent landscape exists around CDK4/6 inhibitors, including synthesis, formulations, and combination therapies.
- Future legal and competitive risks include patent expirations and potential design-arounds through new combination regimens or alternative compounds.
FAQs
1. What is the main innovation of US Patent 9,580,427?
It claims specific methods of treating HR+ breast cancer with CDK4/6 inhibitors, including dosages and combination strategies.
2. How does the scope of this patent compare with the chemical patent rights?
It specifically protects treatment methods rather than compound chemistry, making it narrower but highly relevant for therapeutic use.
3. Are there similar patents from competitors?
Yes. Novartis, Pfizer, and other companies hold patents on CDK4/6 inhibitors and their uses, often overlapping in indications and combination strategies.
4. What could challenge this patent in global markets?
Patent expiration, legal challenges on method claims, and design-around strategies involving new combinations or different dosage schemes.
5. How long is US Patent 9,580,427 enforceable?
Until 2030, with potential extensions if applicable.
References
- U.S. Patent and Trademark Office. (2017). Patent No. 9,580,427.
- Eli Lilly and Company. (2013). Patent family filings related to CDK4/6 inhibitors.
- Kondo, S., & Takakura, H. (2019). Patent landscape for CDK4/6 inhibitors in breast cancer. Journal of Patent Law.
More… ↓
⤷ Start Trial
|
